Effects of Salmeterol in Patients with Persistent Asthma Receiving Inhaled Corticosteroid plus Theophylline

Abstract

Background: Patients with severe asthma require multiple therapies to improve lung function and reduce symptoms. The use of long-acting inhaled β₂-agonists plus theophylline in addition to high doses of inhaled corticosteroids (ICSs) for the treatment of severe asthma has not been extensively studied. Objective: The purpose of this study was to investigate the efficacy and safety of salmeterol combined with high-dose ICSs plus theophylline in severe asthma. Methods: We undertook a randomized, placebo-controlled, crossover study to compare the effect of a single dose of inhaled salmeterol (50 µg) or a placebo in patients with severe asthma whose conditions were not being adequately controlled by therapies with high-dose ICSs plus oral theophylline with or without leukotriene receptor antagonists. Results: Twenty patients took part in the trial. Compared with the placebo, the inhalation of salmeterol significantly increased the FEV₁. Even in the 9 patients treated with high-dose ICSs plus theophylline plus a leukotriene receptor antagonist, the FEV₁ increased significantly more after salmeterol than after the placebo. Conclusion: Patients with severe asthma receiving high-dose ICSs plus theophylline may benefit from the addition of salmeterol.

Regular treatment with salmeterol for chronic asthma: serious adverse events

“…We identified additional references to the included studies and one unpublished study from other reviews (SLGA 3014). A further search in July 2008 generated 48 new references, of which two were relevant to this review (Inoue 2007; Pascoe 2006), but we excluded both as they were short-term crossover studies. We identified no further new studies by the latest searches in August 2009 (79 references) or August 2011 (191 references).…”

Documento de consenso de asma grave en adultos. Actualización 2022

“…De acuerdo con los criterios de AG, estos pacientes estarán recibiendo un tratamiento de mantenimiento con una combinación de GCI/LABA a dosis elevadas, correspondiente al escalón 5 del tratamiento del asma según la GINA o 5-6 según la GEMA 3 , 4 . Si existe control insuficiente de la enfermedad, se añadirá por lo menos uno de los siguientes fármacos: LAMA 3 , 4 , 71 , 72 , 73 , antileucotrieno 74 , teofilina 75 o azitromicina 76 , 77 . En caso de AGNC se estudiará el fenotipo del paciente para establecer la indicación de mAbs.…”

Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment

“…Our SLR identified 113 publications that included data related to the clinical burden of SUA. Twenty-three of these studies, reported in 21 publications, were international studies 13,[96][97][98][99][100][101][102][103][104][105][106][107][108][109][110][111][112][113][114][115] ; others reported data from Asia [14][15][16]19,[116][117][118][119][120][121][122][123][124] , Australia 21,125 , Germany 22,[126][127][128][129] , France 50,54,113,[130][131][132][133] , Italy [29][30]…”